AGILE 3+评分诊断NAFLD患者进展性肝纤维化的准确性:系统综述与Meta分析
该系统综述与Meta分析纳入6项观察性研究共6955例经活检证实的NAFLD患者,评估AGILE 3+评分诊断进展性肝纤维化(≥F3)的准确性。排除切点(≤0.451)敏感度88%、特异度65%;纳入切点(≥0.679)敏感度68%、特异度87%。作者认为AGILE 3+可准确诊断NAFLD进展性肝纤维化,并可识别适合肝活检和新兴药物治疗的患者。
要点
- AGILE 3+评分排除切点≤0.451时敏感度88%(95%CI 81-93%)、特异度65%(95%CI 54-75%)。
- AGILE 3+评分纳入切点≥0.679时敏感度68%(95%CI 57-78%)、特异度87%(95%CI 80-92%)。
- 诊断准确性部分受年龄(P<0.01)和体质指数(P<0.01)影响,性别影响未达统计学显著(P=0.06)。
核心结论
- AGILE 3+评分可准确诊断NAFLD患者的进展性肝纤维化,并可识别适合肝活检和新兴药物治疗的患者。
研究设计与样本
- 系统检索MEDLINE、Ovid Embase、Scopus和Cochrane Library自建库至2023年4月24日的全文文献。
- 纳入6项观察性研究,共6955例经活检证实的NAFLD患者,平均年龄53岁(标准误4),平均体质指数30.9 kg/m²(标准误2.3),男性54.0%,糖尿病患病率59.6%。
- 进展性肝纤维化(≥F3)的合并患病率为42.1%。
主要发现
- 排除切点(≤0.451)的合并敏感度为88%(95%CI 81-93%;I²=89.2%),合并特异度为65%(95%CI 54-75%;I²=97.6%)。
- 纳入切点(≥0.679)的合并敏感度为68%(95%CI 57-78%;I²=91.1%),合并特异度为87%(95%CI 80-92%;I²=96.7%)。
- Meta回归分析显示诊断准确性部分受年龄(P<0.01)和体质指数(P<0.01)影响,性别影响未达统计学显著(P=0.06)。
关键数值与推荐
- AGILE 3+评分排除切点为≤0.451,纳入切点为≥0.679。
临床怎么用
- 作者认为AGILE 3+评分可准确诊断NAFLD进展性肝纤维化,并可识别适合肝活检和新兴药物治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: A simple noninvasive score, the Agile 3+ score, combining liver stiffness measurement, aspartate aminotransferase/alanine aminotransferase ratio, platelet count, diabetes status, sex, and age, has been proposed for the identification of advanced fibrosis in patients with suspected NAFLD. We performed a systematic review and meta-analysis of observational studies to evaluate the diagnostic accuracy of the Agile 3+ score in identifying patients with NAFLD and advanced fibrosis. Recently, an International consensus changed the nomenclature of NAFLD into metabolic-associated steatotic liver disease, so currently, the two terms are interchangeable. APPROACH AND RESULTS: We systematically searched MEDLINE, Ovid Embase, Scopus, and Cochrane Library electronic databases for full-text published articles in any language from the inception to the April 24, 2023. We included original articles reporting data on the sensitivity and specificity of the Agile 3+ score, according to previously described rule-out (≤ 0.451) and rule-in (≥ 0.679) cutoffs. We included 6 observational studies (total of 6955 participants) with biopsy-proven NAFLD [mean age 53 (SE 4) years, mean body mass index 30.9 (SE 2.3) kg/m 2 , 54.0% men, prevalence of diabetes 59.6%]. The pooled prevalence of advanced fibrosis (≥ F3) was 42.1%. By the rule-out cutoff, the overall sensitivity and specificity were 88% (95% CI: 81-93%; I2 = 89.2%) and 65% (95% CI: 54-75%; I2 = 97.6%), respectively. By the rule-in cutoff, the overall sensitivity and specificity were 68% (95% CI: 57-78%; I2 =91.1%) and 87% (95% CI: 80%-92%; I2 =96.7%), respectively. Meta-regression analyses reported that the diagnostic accuracy was partly mediated by age ( p < 0.01), body mass index ( p < 0.01), and, although not statistically significant, sex ( p = 0.06). CONCLUSIONS: Our systematic review and meta-analysis suggests that Agile 3+ accurately diagnoses NAFLD with advanced fibrosis and can identify patients eligible for biopsy and emerging pharmacotherapies.
引用
- Dalbeni A, Lombardi R, Henrique M, et al. Diagnostic accuracy of AGILE 3+ score for advanced fibrosis in patients with NAFLD: A systematic review and meta-analysis. Hepatology. 2023. PMID: 37976417. doi:10.1097/HEP.0000000000000694
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。